<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28464">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968616</url>
  </required_header>
  <id_info>
    <org_study_id>KY-RV-R</org_study_id>
    <nct_id>NCT01968616</nct_id>
  </id_info>
  <brief_title>Ranibizumab Treatment for Retinal Vein Occlusion</brief_title>
  <official_title>Predictive Factors of 2-year Visual Outcome in Retinal Vein Occlusion Following Intravitreal Ranibizumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University, Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <authority>Japan: Ministry of Education, Culture, Sports, Science and Technology</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment
      have not been evaluated comprehensively. Therefore, we have planned to analyze predictors
      for visual outcome from a viewpoint of electrophysiology and biomarkers besides
      morphological features by SD-OCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean foveal thickness measured by SD-OCT</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Macular Edema Due to BRVO/CRVO</condition>
  <arm_group>
    <arm_group_label>Intravitreal Lucentis 0.5mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab, 0.5mg, Intravitreal</intervention_name>
    <arm_group_label>Intravitreal Lucentis 0.5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  Male or female of aged 18 years or older

          -  Macula edema secondary to BRVO/CRVO

          -  Decrease of VA due to macular edema

        Exclusion Criteria:

          -  Prior episode of RVO

          -  Previous treatment with anti-VEGF drugs or corticosteroid or grid laser
             photocoagulation (study eye)

          -  Ocular disorders in the study eye that may confound interpretation of study results

          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for
             RVO

          -  The pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Ophthalmology, Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nagahisa Yoshimura, MD, PhD</last_name>
      <phone>+81-75-751-3248</phone>
      <email>nagaeye@kuhp.kyoto-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Akitaka Tsujikawa, MD. PhD</last_name>
      <phone>+81-75-751-3250</phone>
      <email>tujikawa@kuhp.kyoto-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Nagahisa Yoshimura, M.D, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 20, 2013</lastchanged_date>
  <firstreceived_date>October 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Nagahisa Yoshimura</investigator_full_name>
    <investigator_title>Department of Ophthalmology &amp; Visual Sciences</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
